[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital, Montpellier\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":670},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,183,0,25,[9,45,76,107,137,165,191,217,244,273,297,318,347,374,398,424,449,472,495,526,552,577,601,624,648],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053675","risk-prevention-program-and-therapeutic-patient-education-program-of-patients-with-uncontrolled-epilepsy-100053675",false,"NCT06202196","Risk Prevention Program and Therapeutic Patient Education Program of Patients With Uncontrolled Epilepsy","Evaluate the Impact of a Specific Risk Prevention Program Associated With a Therapeutic Patient Education Program on the Risk Behaviors of Adult Patients With Uncontrolled Epilepsy.","EPI-RISK","Inclusion Criteria:\n\n* Patient between 18 and 60 years old\n* Patient with poorly controlled epilepsy (persistence of seizures evolving for more than a year despite proper treatment) or patient seizure-free for over a year but for whom therapeutic patient education (TPE) would be beneficial according to the investigator..\n* Patient agreeing to participate in a therapeutic education program (TPE)\n\nExclusion Criteria:\n\n* Epileptic patient who has already benefited from a TPE epilepsy program\n* Patients with major cognitive impairment\n* Patient under guardianship or legal protection (safeguard of justice)\n* Pregnant or breast-feeding women\n* Failure to obtain written informed consent after a reflection period\n* Patient who for geographical, social or psychological reasons could not participate in the research\n* Any situation that, in the opinion of the investigator, could present risks to the patient and to the research\n* Participation in another therapeutic research\n* Subjects not covered by public health insurance","ALL","18 Years","60 Years",{"count":22,"type":23},74,"ESTIMATED","INTERVENTIONAL",[26],"NA","Pilot, controled, randomized study aiming to evaluate a plan for the prevention of risks related to epilepsy, 3 months after the last therapeutic patient education session. Two groups of patients will be compared: group \"intervention\" (consultation with the neurologist then a psychologist followed by a session dedicated to risk prevention (\"Recognize and Manage risks\") integrated into usual Therapeutic Patient Education (TPE) versus \"control\" group (usual consultations with the neurologist and usual TPE).\n\n37 subjects per group will be included in this study.",[29],"Epilepsy",[29,31],"Therapeutic Patient Education","RECRUITING","2026-07-09",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2024-04-16",{"date":40,"type":23},"2028-04-16",{"name":42,"class":43},"University Hospital, Montpellier","OTHER",2,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100632588","immun4cure-cohort-of-autoimmune-diseases-100632588","NCT07515638","Immun4Cure Cohort of Autoimmune Diseases","Prospective Cohort Study of Clinical and Biological Data in Patients With Autoimmune Diseases (Immun4Cure Cohort)","Immun4Cure","Inclusion Criteria Participants:\n\nGroup 1: RA\n\n* Adults ≥18 years\n* Patient followed as part of their MAI in one of the departments participating in the study at UHM\n* Confirmed diagnosis according to international criteria :ACR\u002FEULAR 2010\n\nGroup 2: LES\n\n* Adults ≥18 years\n* Patient followed as part of their MAI in one of the departments participating in the study at UHM\n* Confirmed diagnosis according to international criteria :ACR\u002FEULAR 2019\n\nGroup 3: SSc\n\n* Adults ≥18 years\n* Patient followed as part of their MAI in one of the departments participating in the study at UHM\n* Confirmed diagnosis according to international criteria :ACR\u002FEULAR 2013\n\nGroup 4: Healthy Controls\n\n* Adults ≥18 years\n* No symptoms of autoimmune disease\n* No first-degree family history of autoimmune disease\n\nExclusion Criteria (all groupes):\n\n* Patients who have refused or are unable to give informed consent\n* Inability to follow the subject during the study period\n* Participation in another interventional study that includes an exclusion period that is still ongoing\n* Pregnant women\n* Not affiliated with a social security scheme\n* Patients without a national insurance number\n* Persons under judicial protection, guardianship or trusteeship\n* Persons deprived of their liberty",true,{"count":55,"type":23},500,"OBSERVATIONAL","This prospective cohort study aims to constitute a 500-participant database and biobank including 450 adults with systemic autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis) and 50 healthy controls.",[59,60,61,62],"Rheumatoid Arthritis","Systemic Lupus Erythematosus","Systemic Sclerosis","Healthy Adult Volunteers",[64,65,66],"Autoimmune disease","multi-omic profiling","immunology","2026-06-26",{"date":69,"type":36},"2026-06-30",{"date":71,"type":36},"2026-06-23",{"date":73,"type":23},"2034-06-23",{"name":42,"class":43},1,{"id":77,"slug":78,"hasResults":12,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":24,"phases":86,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":75},"100510283","phase-4-daridorexant-to-treat-insomnia-in-patients-with-mild-cognitive-impairment-and-mild-to-moderate-alzheimer-disease-100510283","NCT05924425","Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease","DARIDOR-ALZ","Inclusion criteria :\n\n* Age \\[60-85\\] years old\n* Outpatients\n* Pre-screening:\n\n  * Complaints of dissatisfaction with sleep quantity or quality, despite adequate opportunity for sleep, at least 3 nights per week and for at least 3 months, and\n  * Total sleep time causes clinically significant distress or impairment in daytime functioning, and\n  * Total sleep time estimated by interview was below 6 hours, on at least 3 nights per week and for at least 1 month before screening\n* Baseline PSG (at randomization) assessed TST \\\u003C 6 hours and WASO \\> 1 hour\n* Diagnosis of MCI and AD patients at an early stage according to the NIA diagnosis criteria (core clinical criteria for MCI, positive CSF Aβ42 and\u002For positive plasma biomarker, and neuronal injury (hippocampal and\u002For temporal atrophy by MRI))\n* MMSE from 12 to 26\n* Clinical Dementia Rating CDR from 0.5 to 2\n* Use of CNS-active medications is permitted provided the dose has been stable for at least 3 months, including: anticholinesterase drugs (rivastigmine, donepezil, galantamine) or memantine, antidepressants SSRI (e.g. fluoxetine, sertraline, paroxetine…), SNRI (e.g. venlafaxine, duloxetine), neuroleptics (e.g. clozapine, olanzapine, aripiprazole...) or drug for pain level 2 (codeine, tramadol).\n* For a male subject who is not sterilized and is sexually active with a female partner of childbearing potential, no contraceptive methods are needed\n\nNon inclusion criteria :\n\n* Patients significantly dependent on caregivers\n* Institutionalized patients\n* Analphabetism or subjects unable to read or\u002Fand write\n* Patients unable to perform the neuropsychological tests\n* Patients unable to complete the study instruments (sleep diary)\n* Planned longer stay outside the region that prevents compliance with the visit schedule\n* Patients who cannot be followed up for at least 2 months\n* History of narcolepsy and\u002For cataplexy\n* History of drug or alcohol abuse or addiction\n* History of diagnosed and characterized psychiatric disorders (DSM-5), cured or stabilized (with or without the same treatment for at least 3 months) and excluding any current characterized psychiatric disorder (DSM-5), the diagnosis of which is established by a psychiatrist trained in geriatric psychiatry\n* Moderate and severe liver failure\n* PSG baseline evidence of significant\u002Fsevere sleep-related breathing disorder (defined as \\>30 apnea\u002Fhypopnea episodes per hour)\n* Treatments interfering with sleep-wake patterns\n* Use of hypnotics (benzodiazepines, zolpidem, zopiclone) or drug for pain level 3 (morphine and derivatives)\n* Hypersensitivity to the active substance or to any of the excipients listed in the Summary of Product Characteristics (SmPC)\n* Forbidden and restricted concomitant medications:\n\n  * Concomitant CNS-depressant medicinal products\n  * CYP3A4 inhibitors\n  * CYP3A4 inducers\n* Participation in another clinical trial or administration of an investigational product\n* Protected population according to articles of the French Public Health Code (e.g. patients under law protection, prisoners, pregnant, parturient or lactating women, and patients under guardianship\u002Fcuratorship).\n* Subjects not covered by public health insurance\n* Failure to obtain written informed consent after a reflection period","85 Years",{"count":85,"type":23},62,[87],"PHASE4","DARIDOR-ALZ is a phase IV clinical trial designed to evaluate both the efficacy and safety of daridorexant, a selective dual orexin receptor antagonist that blocks the actions of the orexin neuropeptides at both orexin-1 and orexin-2 receptors, in selected populations of MCI and mild-to-moderate AD patients with insomnia complaints.",[90,91,92],"Alzheimer Disease","Insomnia Disorder","Sleep",[94,95,96,97,92,98],"Orexin","Daridorexant","Cognition","Alzheimer","Insomnia","2026-06-24",{"date":101,"type":36},"2026-06-25",{"date":103,"type":36},"2024-03-13",{"date":105,"type":23},"2028-03-13",{"name":42,"class":43},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":18,"minAge":114,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":24,"phases":117,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":75},"100607497","phase-3-a-prospective-randomized-non-inferiority-trial-comparing-anti-cd20-maintenance-versus-de-escalation-strategy-in-relapsing-remitting-multiple-sclerosis-100607497","NCT07189325","A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis","DESIRE MS","Inclusion criteria :\n\n* Patients ≥40 years at inclusion\n* Patients with relapsing remitting multiple sclerosis at inclusion (according to 2017 McDonald criteria) treated with anti-CD20 for at least the last 3 years. For patients treated with IV ocrelizumab or rituximab at extended interval dosing, a maximum interval of 12 months between perfusions during the year before inclusion visit is required.\n* No evidence of disease activity for the last 3 years on anti-CD20 (No relapse AND no new\u002Fenlarged MRI lesion)\n* Brain MRI performed according to OFSEP protocol within a maximum of 6 months before randomization\n\nNon-inclusion criteria :\n\n* Secondary or primary progressive MS at inclusion\n* Previous experience of treatment failure in patients treated with natalizumab, fingolimod, rituximab, ocrelizumab, mitoxantrone, alemtuzumab or cladribine\n* Treatment with high dose corticosteroids during the 30 days preceding inclusion\n* Contraindication to MRI\n* Severely immunocompromised state\n* Current severe active infection\n* Known active malignancy\n* Severe heart failure (New York Heart Association Class IV) or severe, uncontrolled cardiac disease\n* Severe hepatic impairment (Child-Pugh class C)\n* Significantly impaired bone marrow function or significant anaemia, leukopenia, neutropenia or thrombocytopenia\n* Severe renal impairment undergoing dialysis\n* Severe hypoproteinaemia, e.g. in nephrotic syndrome\n* Current severe depression and\u002For suicidal ideation\n* Suspected or confirmed progressive multifocal leukoencephalopathy (PML)\n* Any condition that, in the opinion of the investigator, would interfere with the interpretation of patient safety or place the patient at high risk for treatment-related complications\n* Participation in another therapeutic trial in the last 6 months\n* Protected population according to articles of the French Public Health Code (e.g. patients under law protection, prisoners, pregnant, parturient or lactating women, and patients under guardianship\u002Fcuratorship)\n* All women of childbearing age not using effective contraception during the study\n* Subjects not covered by public health insurance\n* Failure to obtain written informed consent after a reflection period","40 Years",{"count":116,"type":23},250,[118],"PHASE3","Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost. It commonly starts during the third and fourth decades. Over the last twenty years, several disease-modifying therapies with variable benefit\u002Frisk profiles have been introduced leading to dramatic changes in the prognosis of MS.\n\nFirst, several moderately effective therapies , with good safety profile, have allowed to decrease the frequency of relapses along with a possible, albeit limited, effect on medium- and long-term disability.\n\nMore recently highly effective therapies (HET), with immunosuppressive properties, have dramatically reduced clinical and MRI disease activity and significantly improved patient's prognosis.\n\nAnti-CD20 therapies (B-cells depleting therapies, given either intravenous or subcutaneous), one of the main HET, have demonstrated higher efficacy than platform therapies in several phase 3 randomized clinical trials and their use within the very first years of the disease seems to be associated with improved long-term outcomes.\n\nTaking all of this into account, the investigators hypothesize that RRMS patients who experience a de-escalation from anti-CD20 therapies to platform therapies after 40 years will not experience disease activity accrual and disability worsening.",[121,122],"Relapsing-Remitting Multiple Sclerosis (RRMS)","Anti-CD20 Therapy",[124,125,126,127,128,129],"Multiple Sclerosis","High efficacy therapies","de-escalation","adverse events","relapses","escalation","2026-06-22",{"date":71,"type":36},{"date":133,"type":36},"2026-06-15",{"date":135,"type":23},"2031-06",{"name":42,"class":43},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":75},"100644212","efficacy-of-islet-re-transplantation-after-failure-of-beta-cell-replacement-100644212","NCT07666789","Efficacy of Islet Re-transplantation After Failure of Beta-cell Replacement","Efficacy and Safety of Islet Re-transplantation After Failure of Beta-cell Replacement","MULT-ILOT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of type 1 diabetes\n* Prior beta-cell replacement therapy : islet transplantation or pancreas transplantation\n* Islet re-transplantation performed after 2005\n* Islet re-transplantation performed after documented beta cell graft failure, defined by undetectable C-peptide and\u002For recurrence of severe hypoglycemia on insulin therapy\n* Availability of clinical and biological data required for assessment of study outcomes\n\nExclusion Criteria:\n\n* Missing or incomplete data preventing assessment of the primary outcome\n* Patients who did not meet inclusion criteria",{"count":146,"type":23},20,"Islet transplantation and pancreas transplantation are established therapeutic options for selected individuals with type 1 diabetes experiencing severe glycemic instability and recurrent hypoglycemia. Although these approaches significantly improve glycemic management and quality of life, long-term graft survival remains limited, with a progressive decline in beta-cell function over time.\n\nThe clinical benefit-risk profile of islet re-transplantation after graft failure remains poorly defined, and outcomes following repeat islet transplantation after prior islet graft failure have not been specifically evaluated.\n\nRepeated exposure to multiple donors may increase the risk of alloimmunization, including the development of donor-specific antibodies , which may adversely affect graft survival and limit access to future transplantation.\n\nThis multicenter retrospective cohort study aims to evaluate the efficacy and safety of islet re-transplantation in adults with type 1 diabetes after failure of initial beta-cell replacement (islet or pancreas transplantation), with outcomes assessed at 3 months, 1 year, and 5 years.",[149,150],"Type 1 Diabetes (T1D)","Islets of Langerhans Transplantation",[152,153,154,155,156,157],"islet transplantation","pancreas transplantation","type 1 diabetes","beta cell replacement","graft survival","glycemic control","2026-06-21",{"date":99,"type":36},{"date":161,"type":36},"2025-07-31",{"date":163,"type":23},"2026-09-30",{"name":42,"class":43},{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":53,"sex":18,"minAge":19,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":175,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":75},"100618920","conceptualizing-borderline-personality-disorder-as-a-relationship-use-disorder-100618920","NCT07337889","Conceptualizing Borderline Personality Disorder as a Relationship Use Disorder","TLUR","Inclusion Criteria:\n\n* General : aged 18-45\n* Specific :\n* Borderline personality disorder (BPD)assessed by SCID, without bipolar disorder\n* Bipolar disorder (assessed by SCID), without BPD (evaluated by SCID)\n* Healthy controls with no psychiatric disorders (screened by SCID).\n\nExclusion Criteria:\n\n* Psychotic disorders (evaluated by SCID)\n* lack of informed consent\n* Not affiliated with social security\n* Under judicial or administrative confinement or involuntary hospitalization\n* Protected by law (e.g., under guardianship)\n* Pregnancy or breastfeeding\n* Inability to understand, speak, or write in French\n* Inability to understand the study's purpose or methodology\n* Excluded from another study during the exclusion period\n* Participants who have received over €6000 in annual indemnities\n* For Bipolar Participants (without BPD) : Current moderate or severe depressive episode (BDI score \\> 18) or Current hypomanic\u002Fmanic episode (YMRS \\\u003C 12)","45 Years",{"count":174,"type":23},194,[26],"This study aims to explore a novel conceptualization of Borderline Personality Disorder (BPD) as a \"Relationship Use Disorder.\" The research proposes that BPD shares key features with behavioral addictions, specifically addiction to interpersonal relationships. The study builds upon previous findings suggesting that individuals with BPD experience intense emotional dysregulation, including negative self-perception, shame, and a compulsive need for external validation. This addiction to relationships, much like substance use disorders, is thought to contribute significantly to the difficulties faced by these individuals, including interpersonal conflicts, self-destructive behaviors, and emotional instability.\n\nThe study seeks to demonstrate that the relational difficulties central to BPD meet the diagnostic criteria for addiction as defined by the DSM-5. It will also explore how these relational struggles are mediated by dysfunctional self-perception and whether they are linked to behaviors such as compulsive sexual behaviors (CSBD) or suicidal tendencies. Additionally, the research will investigate the relationship between addiction to relationships and neurobiological factors, including endorphin levels, in individuals with BPD compared to those with bipolar disorder and healthy controls. The hypothesis is that individuals with BPD will exhibit higher levels of relationship addiction, with this addiction being tied to their perception of self-worth and emotional experiences in relationships.\n\nThis innovative approach aims to refine the understanding of BPD, reduce stigma, and improve treatment strategies by providing scientific evidence supporting the conceptualization of BPD as a \"Relationship Use Disorder.\"",[178,179,180],"Borderline Personality Disorder","Borderline Personality Disorder (BPD)","Bipolar Disorder (BD)",[182,183],"borderline personality disorder","relationship-use disorder","2026-06-18",{"date":130,"type":36},{"date":187,"type":36},"2026-06-01",{"date":189,"type":23},"2028-08-01",{"name":42,"class":43},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":53,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":201,"conditions":202,"keywords":205,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":75},"100491653","platform-for-the-prospective-mother-child-study-of-the-determinants-of-neurodevelopmental-disorders-100491653","NCT05681923","Platform for the Prospective Mother-child Study of the Determinants of Neurodevelopmental Disorders","Platform for the Prospective Mother-child Study of the Determinants of Autism Spectrum Disorder and Neurodevelopmental Disorders Neurodevelopmental Disorders","MARIANNE","INCLUSION CRITERIA:\n\nGeneral inclusion criteria (High risk and Low risk cohorts)\n\nMother:\n\n* Be pregnant (single or multiple pregnancy), at least 16 weeks of amenorrhea,\n* Have at least one biological child of 24 months or older,\n* At least 18 years of age\n\nFather:\n\n* Be the biological father of the unborn child,\n* At least 18 years of age\n\nUnborn Child:\n\n\\- Have a woman study participant as mother.\n\nSpecific inclusion criteria for the High risk cohort:\n\n* Autistic sibling: refers to the biological child(ren) of the mother and\u002For father participating in the study and being the parent(s) of the unborn child\n* Be at least 24 months old and less than 18 years old,\n* Have a confirmed diagnosis of Autism Spectrum Disorder based on medical records. If in doubt, the SRS-2 (Social Responsiveness Scale for Adults) and PEDS-DM (Parents' Evaluation of developmental status) questionnaires will be completed. Only children with positive scores on one of these questionnaires will be included after validation of the diagnosis by an expert committee,\n* In case of several children with Autism Spectrum Disorder based in the siblings, only the last born will be included.\n\nRemarks:\n\n* Autism Spectrum Disorder siblings resulting from a medically assisted procreation are eligible provided that part of the genetic heritage is common to that of the mother or father of the unborn child participating in the study.\n* If the father does not live with the mother of the unborn child, his participation is not required and does not preclude the participation of other family members.\n\nEXCLUSION CRITERIA:\n\nGeneral non-inclusion criteria (High risk and Low risk cohorts):\n\nFather and mother:\n\n* Unable to understand French or the study questionnaires\n* Participant on protective measures (guardianship or curatorship) or deprived of liberty by judicial or administrative decision, or subject to a legal protection measure\n* Not affiliated to a social security system\n* Refusal to participate. In the case of consent given for the born and unborn child, the consent must be given by the person(s) with parental authority.\n* Live at a distance from the recruitment center incompatible with follow-up.\n\nSpecific non-inclusion criteria for the Low risk cohort:\n\nMother and\u002For father of unborn child:\n\n\\- Have a biological child with a diagnosis of Autism Spectrum Disorder or other neuro developmental disorder",{"count":200,"type":23},7320,"Neurodevelopmental disorders such as attention deficit disorder with or without hyperactivity, autism spectrum disorder, language and social communication disorder, motor coordination disorder, learning disorder (dyslexia, dyscalculia, dysorthography), intellectual development disorder are frequent and long-lasting developmental difficulties that can be observed in children in various domains. They are often associated and have a significant impact on daily functioning at school and at home.\n\nThe rate of people affected by neurodevelopmental disorders including autism spectrum disorder have increased significantly over the past 20 years. Improved screening only partly explains this evolution.\n\nA genetic predisposition plays an important role in the occurrence of these disorders, however, current scientific data suggest a multifactorial origin. Exposures such as those related to the use of pesticides, air pollution or the presence of endocrine disruptors in our diet could be involved in the genesis of neurodevelopmental disorders, particularly during intrauterine life, a period of great vulnerability.\n\nThe current diagnostic pathways for autism rarely enable the early identification of babies at risk. Without early detection and timely targeted intervention, these children have a poor health outcome and do not reach their full potential.\n\nThe general objective of the MARIANNE cohort is to constitute a French research infrastructure dedicated to research on the biological and environmental determinants of neurodevelopmental disorders including autism.\n\nThis cohort is based on the follow-up of 1200 families with already a child affected by an autism spectrum disorder, which implies a high risk of neurodevelopmental disorders including autism spectrum disorder for the siblings, and of 500 families from the general population with no excess risk of neurodevelopmental disorders. The total number of subjects to be included (mother, father, unborn child and ASD sibling for the HR group) is thus 6300.\n\nThe inclusion of these families will be at the beginning of a new pregnancy and the follow-up will be carried out from the second trimester of pregnancy until the children are 6 years old, the age at which the diagnosis of neurodevelopmental disorders is possible.\n\nBiological, clinical, social and environmental data will be collected at different stages of the follow-up and will be included into a large database.",[203,204],"Autism Spectrum Disorder","Neurodevelopmental Disorders",[206,207,208,209,210],"exposome","child development","genome","risk factors","prenatal cohort",{"date":130,"type":36},{"date":213,"type":36},"2023-04-19",{"date":215,"type":23},"2034-03",{"name":42,"class":43},{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":24,"phases":228,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":243},"100630878","phase-2-phase-iia-trial-of-anti-cd19-car-t-cells-in-systemic-sclerosis-resistant-to-immunosuppressive-therapy-100630878","NCT07493395","Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy","SCLEROCAR: A Phase IIa Trial Evaluating the Efficacy of Anti-CD19 Chimeric Antigen Receptor Engineered T-Cells in Patients With Systemic Sclerosis (SSc) Resistant to Immunosuppressive Drugs","SCLEROCAR","Pre-Inclusion criteria:\n\n1. Diagnosis of systemic sclerosis according to ACR\u002FEULAR 2013 classification (15).we include in the critera the fulfilling of 2013 EULAR\u002FACR criteria and specify disease duration (less than 2 years), score\u002Fclinical evidence for active disease :\n2. Severe and resistant to low dose steroids and at least 2 immunosuppressive treatment including csDMARDs (methotrexate, azathioprine, mycophenolate mofetil) and at least one bDMARDs (Tocilizumab)\n3. Early onset (less than 2 years).\n4. Severity \\& progression of disease be defined by :\n\n   1. .mRSS \\>15 with at least one organ involvement (lung: FVC \\\u003C80%, renal involvement, cardiac involvement, Creatinine \\\u003C 1.5 mg\u002Fdl within 6 months).\n   2. mRSS \\\u003C15 and lung fibrosis progression (FVC -10% DLCO -15% within 6 months)\n5. patients with active disease (as defined by EUSTAR ≥2.5) and to patients with a worsening disease despite 6 months of at least 2 immunosuppressive treatments including one DMARDs (methotrexate, azathioprine, mycophenolate mofetil), and one biological DMARD rituximab or tocilizumab.\n6. Estimated survival time \\> 24 weeks\n7. Age: ≥18 ≤64 years old voluntary to participate in the study and sign the informed consent\n8. Adequate organ functions assessed :\n\n   1. serum Creatinine clearance \\> 40ml\u002Fmi\n   2. adequate bone marrow function (Hemoglobin ≥9g\u002FdL ; PMN ≥ 1 G\u002FL ; Platelets ≥ 100 G\u002FL)\n   3. Alanine aminotransferase (ALT) ≤ 3 x ULN and total bilirubin \\\u003C 2.0 mg\u002FdL (34 μmol\u002FL) (or \\\u003C 3.0 mg\u002FdL \\[51 μmol\u002FL\\] for subjects with Gilbert's syndrome)\n   4. Adequate respiratory function: no dyspnea or grade I dyspnea (Common Terminology Criteria for Adverse Events (NCI CTCAE v 5.0) and oxygen saturation \\>\u002F= 92% on room air\n9. Highly effective contraception methods\n\nInclusion criteria:\n\n1. Adequate organ functions assessed:\n\n   1. serum Creatinine clearance \\> 40ml\u002Fmi\n   2. adequate bone marrow function (Hemoglobin ≥9g\u002FdL ; PMN ≥ 1 G\u002FL ; Platelets ≥ 100 G\u002FL)\n   3. Alanine aminotransferase (ALT) ≤ 3 x ULN and total bilirubin \\\u003C 2.0 mg\u002FdL (34 μmol\u002FL) (or \\\u003C 3.0 mg\u002FdL \\[51 μmol\u002FL\\] for subjects with Gilbert's syndrome)\n   4. Adequate respiratory function: no dyspnea or grade I dyspnea (Common Terminology Criteria for Adverse Events (NCI CTCAE v 5.0) and oxygen saturation \\>\u002F= 92% on room air\n2. Adequate venous access for apheresis\n3. Leucapheresis : a wash-out period of 6 weeks for conventional immunosuppressants (i.e. methotrexate, mycophenolate mofetil)\n4. Leucapheresis : at least 12 weeks after biotherapy (i.e. tocilizumab, 6 months for rituximab),\n\nExclusion Criteria:\n\n1. Craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular ischemia or cerebrovascular hemorrhagic diseases\n2. ECG showing prolonged QT interval or history of severe heart diseases or FEVG \\\u003C 40%\n3. Lung and \u002F or heart severe dysfunction defined by CVF\\\u003C50% and\u002For DLCO \\\u003C40%\n4. Pulmonary arterial hypertension defined by catheterism (mean AP \\> 25mmHg at rest or \\> 30mmHg after exercise, PAOP \\\u003C 15mmHG)\n5. Clinically significant active, opportunistic, chronic or recurrent infection (including but not limited to: hepatitis B or C virus or HIV) or covid-19 \\\u003C 1 months including active or latent tuberculosis (TB) infection\n6. Contra indication for autologous hematopoietic stem cell transplantation (AHSCT ) or relapsing at least one year after AHSCT\n7. Active hematological or solid neoplasm\n8. Concurrent therapy with systemic steroids (\\>10 mg\u002Fd prednisone equivalent) within 2 weeks prior to inclusion, except inhaled steroids\n9. Methylprednisolone or prednisone (maximum dose 20 mg) instead of immunosuppressive agents\n10. T cell targeting drugs (e.g. mycophenolate mofetil, azathioprine, calcineurin inhibitors) within 6 weeks prior to leukapheresis\n11. Previous adoptive T cell therapy or any gene therapy including CAR T cell therapy\n12. Live vaccines within 6 weeks prior to leukapheresis\n13. Hypersensitivity against any drug or its ingredients\u002Fimpurities that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory preparative chemotherapy or rescue medication\u002Fsalvage therapies for treatment related toxicities\n14. patients without social security coverage;\n15. patients under guardianship;\n16. Male or female patients seeking to conceive a child\n17. Women of childbearing potential unless they are using a highly effective method of contraception starting from the time of enrolment and for at least 12 months following LD chemotherapy and until clearance of CAR-T cells, and sexually active male participants unwilling to use a condom. Female partners of sexually active male participants must be on a highly effective form of birth control from the time of enrolment and for at least 12 months following LD chemotherapy and until clearance of CAR-T cells.\n18. pregnant or breastfeeding women;\n19. patients with advanced cognitive disorders or any other cause preventing their informed consent;\n20. active, clinically significant CNS pathology : If signs or symptoms exist which present diagnostic uncertainty, neurologist consultation will be obtained to confirm the diagnosis of any neurological condition\n21. any comorbidity, whatever it may be, which may, in the opinion of the investigator, place the patient at additional risk or interfere with the monitoring of the study.\n22. Concurrent participation in any other interventional trial and Contraindication to the lymphodepleting chemotherapy","64 Years",{"count":227,"type":23},6,[229],"PHASE2","The goal of this clinical trial is to evaluate whether anti-CD19 CAR T-cell therapy can improve disease activity in adults with severe, treatment-resistant systemic sclerosis (SSc). The study will also assess the safety of this therapy and how CAR T-cells behave in the body.\n\nThe main questions are:\n\nDoes CAR T-cell therapy reduce skin thickening and other signs of SSc? What side effects occur after receiving CAR T-cells? How do CAR T-cells expand, persist, and affect B-cells and autoantibodies?\n\nParticipants will:\n\nUndergo leukapheresis Receive short lymphodepleting chemotherapy Receive one infusion of anti-CD19 CAR T-cells Stay in the hospital for about 10 days Attend follow-up visits for 24 months with clinical exams, blood tests, and organ-function assessments\n\nOptional skin or lymph-node biopsies may be performed in participants who consent to these procedures.\n\nThis study aims to provide early evidence on whether CAR T-cell therapy could become a promising treatment option for systemic sclerosis.",[232],"Scleroderma, Systemic",[61,234,235],"Anti-CD19 CAR T-cells","Autologous CAR T-cell therapy","2026-06-17",{"date":130,"type":36},{"date":239,"type":36},"2026-06-11",{"date":241,"type":23},"2028-06-11",{"name":42,"class":43},4,{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":254,"conditions":255,"keywords":258,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":4},"100624387","prospective-twin-pregnancy-cohort-at-montpellier-university-hospital-100624387","NCT07408973","Prospective Twin Pregnancy Cohort at Montpellier University Hospital","Twin Pregnancy Cohort at Montpellier University Hospital for a Study of the Impact of the Exposome: Pilot Study","COGEM","Mother's inclusion Criteria:\n\n* Patient of legal age (≥ 18 years)\n* Patient pregnant with a twin pregnancy ≥ 25 weeks of gestation\n* Pregnancy initially twin, triplet, or quadruplet, progressing to a twin pregnancy after spontaneous or medical embryo reduction, or after selective termination of pregnancy\n* Delivery planned at Montpellier University Hospital\n\nTwins' inclusion Criteria:\n\n* Twins born in a twin pregnancy ≥ 25 weeks of gestation\n\nMother's exclusion Criteria:\n\n* Pregnant woman with at least one fetus presenting with a chromosomal or genetic abnormality or a polymalformative syndrome, and for whom early postnatal death is anticipated.\n* Planned travel preventing the study from being completed\n* Failure to obtain informed and written consent from the patient for participation in the study and the collection of biological samples\n* Patient unable to read and\u002For write French\n* Patient unable to understand and\u002For speak French\n* Patient not benefiting from a national health insurance scheme\n* Person under legal protection, guardianship or curatorship\n* Person participating in other interventional research study\n\nTwins' exclusion Criteria:\n\n* Mother's absence from or withdrawal from the study\n* Birth in a facility other than Montpellier University Hospital\n* One or two children under guardianship\n* Lack of informed and written consent from legal representatives\n* One of the two fetuses is expected to die\n* Lack of informed and written consent from the prospective parent(s) for participation in the study and the collection of biological samples\n* Parents unable to read and\u002For write French\n* Parents not understanding and\u002For speaking French",{"count":253,"type":23},360,"This prospective observational cohort study aims to investigate the impact of the maternal and early-life exposome on neonatal and early childhood health outcomes in twin pregnancies followed at University Hospital of Montpellier (France). Grounded in the Developmental Origins of Health and Disease (DOHaD) framework, the study focuses on how environmental, biological, and lifestyle exposures during pregnancy and the first year of life influence fetal growth, neonatal health, and early development.\n\nA total of 120 women with monochorionic or dichorionic twin pregnancies and their 240 children will be included. Maternal exposome assessment includes air pollution exposure, lifestyle, diet, medical history, and biological measurements. Neonatal outcomes, including abnormal birth weight, will be evaluated at birth, and children will be followed until one year of age to assess growth, health events, and developmental outcomes. Biological samples collected at different times during the study will allow the assessment of chemical exposures and epigenetic markers. This study aims to generate original French twin pregnancy data and to improve understanding of environmental determinants of early-life health.",[256,257],"Pregnancy","Twin",[259,260,261,262,263,264,265],"Exposome","Air Pollutants","Lead","Diet, Food, and Nutrition","Healthy Lifestyle","Obstetric Labor Complications","Children Health","NOT_YET_RECRUITING",{"date":184,"type":36},{"date":269,"type":23},"2026-12",{"date":271,"type":23},"2030-12-01",{"name":42,"class":43},{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":24,"phases":283,"briefSummary":284,"conditions":285,"keywords":287,"overallStatus":266,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":294,"leadSponsor":296,"locationsCount":227},"100622064","phase-2-comparing-udca-and-corticosteroids-in-immunotherapy-induced-cholestatic-hepatitis-100622064","NCT07378761","Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis","Efficacy of Ursodeoxycholic Acid Versus Corticosteroids for the Treatment of Cholestatic Hepatitis Secondary to Immunotherapy: A Multicenter, Controlled, Randomized, Open Trial","CHILURSO","Inclusion Criteria:\n\n* Adults ≥18 years old\n* Any type of cancer except hepatocellular or cholangiocarcinoma\n* At least one ICI injection\n* Cholestatic hepatitis Grade CTC-AE 3 or 4\n\nExclusion Criteria:\n\n* Ongoing corticosteroids treatment\n* Other causes of hepatitis\n* Cirrhosis\n* ICI for hepatocellular carcinoma or cholangiocarcinoma\n* Biliary obstruction\n* Medical contraindication to corticosteroids or UDCA\n* Mixed or hepatocellular hepatitis\n* Total bilirubin \\> 1,5 ULN, Prothrombin rate \\\u003C 70%\n* Medical contraindication to MRI or liver biopsy\n* Oher serious side effects requiring corticosteroids\n* Pregnant and breast-feeding patients\n* Patients under articles L1121-5 to 8 of the public health code\n* Lack of informed consent\n* Patients not affiliated with French social security system\n* Patients uncapable of understanding french",{"count":282,"type":23},94,[229],"The clinical trial aims to compare the effectiveness of ursodeoxycholic acid (UDCA) to corticosteroids in treating cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs) over a 21-day period.\n\nThe trial presents a detailed scientific justification for comparing UDCA to corticosteroids, describing the treatment and detailing the follow-up procedures. It hypothesizes that UDCA could be superior to corticosteroids for treating ICI-related cholestatic hepatitis, based on its established use in primary biliary cholangitis and a favorable tolerance profile compared to corticosteroids.",[286],"Immune-Mediated Cholestasis",[288,289,290,291],"DILI","Immune checkpoint inhibitors","Cancer","Cholestatic hepatitis",{"date":184,"type":36},{"date":269,"type":23},{"date":295,"type":23},"2029-08",{"name":42,"class":43},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":53,"sex":305,"minAge":4,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":24,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":75},"100595150","early-luteal-phase-progesterone-kinetics-after-hcg-induced-ovulation-in-modified-natural-cycle-100595150","NCT07028710","Early Luteal Phase Progesterone Kinetics After hCG-Induced Ovulation in Modified Natural Cycle","Evolution of Luteal Progesteronemia in a Modified Natural Cycle (Ovulation Triggered by hCG): Pilot Study","CineP4","Inclusion Criteria:\n\n* At least 1 follicle of 14 mm or more\n* Endometrium of 6 mm or more\n* Plasma luteinizing hormone (LH) less than 2 times basal level (measured at the beginning of the cycle between D1 and D4) and progesteronemia less than 1.5 ng\u002FmL\n* For whom ovulation induction with recombinant hCG (Ovitrelle) is then proposed (standard care).\n\nExclusion Criteria:\n\n* Patient whose venous capital contraindicates repeated blood sampling over a short period of time over a short period.\n* Patient treated with exogenous natural progesterone (vaginal or injectable) which may interfere or synthetic progesterone, which may interfere with endogenous progesterone secretion.\n* Patient who has not given written consent to participate in the study.\n* Patient not fluent in French.\n* Patient under guardianship, curators or without social security coverage.\n* Patient participating in another study with an ongoing exclusion period or other interventional research with no ongoing exclusion period involves the use of a drug or procedure capable of altering progesterone levels .","FEMALE",{"count":307,"type":23},40,[26],"This pilot study evaluates how progesterone levels change after hCG-triggered ovulation in modified natural cycles. Forty women preparing for frozen embryo transfer will have blood tests over 6 days to monitor hormone levels. The goal is to understand whether hCG affects the timing of the luteal phase and embryo implantation.",[311],"Luteal Phase Insufficiency",{"date":130,"type":36},{"date":314,"type":36},"2026-01-12",{"date":316,"type":23},"2030-06-15",{"name":42,"class":43},{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":324,"eligibilityCriteria":325,"healthyVolunteers":53,"sex":305,"minAge":19,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":329,"conditions":330,"keywords":333,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":75},"100595794","understanding-cycles-to-improve-womens-health-100595794","NCT07037082","Understanding Cycles to Improve Women's Health","Understanding Socio-ecological Variation in Menstrual Cycles to Advance Female Health","C-HEALTH","Inclusion Criteria:\n\n* Woman of childbearing age (18-39 years)\n* Woman not using hormonal contraception for at least 6 months\n* Woman with semi-regular menstrual cycles between 21 and 45 days inclusive\n* Woman with no known history of infertility\n* Woman working in the same environment (urban\u002Frural) as her place of residence\n* Knowledge of the dates of periods over the last 3 cycles\n* Woman who has a freezer at -20°C\n\nExclusion Criteria:\n\n* Diagnosis by a physician of one or more of the following comorbidities: Polycystic ovarian syndrome (PCOS), Endometriosis, Adenomyosis, Diabetes or thyroid disease, Hormone-dependent gynecological cancers (breast, endometrium, ovaries), Coagulation diseases (von Willebrand), Chronic liver failure, chronic renal failure, heart disease, autoimmune disease, Autism, Diagnosis and\u002For treatment for a psychiatric illness\n* Chronic exposure to cocaine, amphetamine\u002Fmethamphetamine, morphine or ecstasy within 30 days prior to inclusion\n* Chronic exposure to THC within 7 days prior to inclusion.\n* Person who is not comfortable with self-sampling (hematophobia or other)\n* No access to a smartphone\n* No possibility of wearing a connected ring for at least 60 days 22h\u002F24h\n* Pregnant or breastfeeding woman\n* Woman who gave birth or breastfed in the 2 months before the study\n* Person who moved less than 2 years before the study (does not concern participants who moved in the same environment (rural or urban, less than 20 km)\n* Person unable to read French\n* Failure to obtain informed consent\n* Person not benefiting from a national health insurance scheme\n* Person under legal protection, guardianship or curatorship\n* Person participating in other research involving the human person","39 Years",{"count":328,"type":23},320,"Introduction:\n\nThe C-HEALTH study investigates how environmental and socio-economic conditions affect women's menstrual cycles and reproductive health.\n\nAim:\n\nTo compare progesterone levels during the luteal phase among women from different socio-economic backgrounds living in rural and urban areas in southern France.\n\nMethods:\n\nThis is a prospective observational study involving 320 healthy women of reproductive age.\n\n* Hormones (progesterone, estradiol) will be measured daily in saliva.\n* Inflammation (Protéine C Réactive: CRP) will be measured five times per cycle via blood drops.\n* Participants will wear a smart ring to monitor body temperature and activity.\n* Daily symptoms and lifestyle data will be collected.\n* Environmental exposures (pollution, stress, living conditions) will be assessed and linked to menstrual health outcomes.",[331,332],"Woman of Reproductive Age","Socioeconomic Factors",[334,259,335,336,337,338,339,340],"Menstrual Cycle","Hormones","Inflammation","Rural\u002FUrban","Socioeconomic status","Pollution","Ovulation",{"date":130,"type":36},{"date":343,"type":36},"2025-09-01",{"date":345,"type":23},"2029-07-01",{"name":42,"class":43},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":355,"targetDuration":356,"studyType":56,"phases":4,"briefSummary":357,"conditions":358,"keywords":362,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":75},"100582528","prospective-cohort-of-immune-checkpoint-inhibitor-induced-hepatitis-100582528","NCT06864481","Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis","Description, Course and Treatment of Immune Checkpoint Inhibitor-induced Hepatitis","CO-CHILI","Inclusion criteria:\n\n* Age ≥ 18 years\n\n  * Patient willing to participate in the study\n  * Patient with cancer receiving neoadjuvant, adjuvant, or maintenance treatment · Patient treated with ICI, either as monotherapy or in combination with another antitumor treatment (targeted therapy, chemotherapy, or radiotherapy), either de novo or after a first-line treatment including ICIs\n  * Patient who has received at least one injection of an ICI ·\n  * Onset of hepatitis following treatment initiation, defined by the following criteria:\n\n    * ALT (alanine aminotransferase) ≥ 5 times the upper normal limit\n    * ALP (alkaline phosphatase) ≥ 2 times the upper normal limit\n    * ALT (alanine aminotransferase) ≥ 3 times the upper normal limit and bilirubin ≥ 2 times the upper normal limit ·\n  * Patient with grade 3 or 4 hepatitis, according to the current CTCAE classification\n  * Exclusion criteria:\n* Patient with another cause of acute hepatitis, including viral, autoimmune, ischemic, acute alcoholic hepatitis, or Wilson's disease.\n* Patient unable to express their non-opposition to participate in the study.\n* Person deprived of liberty, under guardianship or curatorship, or in an emergency situation.\n* Person not affiliated with a social security system or without entitlement to healthcare coverage.",{"count":116,"type":23},"12 Months","Background and Study Rationale Immune checkpoint inhibitors (ICI) are a breakthrough cancer treatment that boosts the immune system to fight tumors. While effective, they can cause immune-related side effects, including liver inflammation (ICI-induced hepatitis or CHILI), which affects up to 25% of patients. Severe cases requiring treatment discontinuation are rare but challenging to manage.\n\nStudy Objective This multicenter prospective study aims to better understand CHILI, its clinical patterns, treatment response, and risk of recurrence. It will focus on different types of liver injury (cholestatic, hepatocellular, or mixed) to guide better treatment decisions.\n\nInnovation and Approach Currently, there is no clear consensus on how to manage CHILI or when to safely restart immunotherapy. This study will collect real-world data from adult patients treated with ICIs, following international guidelines or a pragmatic approach when no consensus exists. Findings will help improve care strategies for patients experiencing ICI-related liver toxicity.",[359,360,361],"Liver Injury","Secondary to Immune Checkpoint Inhibitors","Cancer Patients",[289,363,364,365,366,367],"Immunotherapy","Drug-induced liver injury","Hepatitis","Cholangitis","Ursodeoxycholic acid",{"date":184,"type":36},{"date":370,"type":36},"2025-04-22",{"date":372,"type":23},"2028-04-22",{"name":42,"class":43},{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":24,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":75},"100563637","motivational-interviews-post-hospitalisation-on-maintaining-abstinence-for-1-year-aprs-le-sevrage-en-alcool-100563637","NCT06618755","Motivational Interviews Post Hospitalisation on Maintaining AbstiNence for 1 Year après le Sevrage en Alcool","IMMANENCE - Intérêt d'un Suivi Sous Forme d'Entretiens Motivationnels spécifiques Post Hospitalisation Sur le Maintien de l'AbstiNENCE Durant l'année Suivant le Sevrage en Alcool","IMMANENCE","Inclusion Criteria:\n\n* With alcohol use disorders defined by at least 2 DSM-V criteria for at least 12 months).\n* Being treated for withdrawal in hospital.\n* With a goal of complete abstinence.\n* With a means of communication (telephone).\n\nExclusion Criteria:\n\n* Lack of understanding (written and spoken) of the French language.\n* Breach of HC withdrawal contract, following failure to comply with the rules of the addictology service and somatic complications of addiction.\n* Eviction from the department, discharge against medical advice during hospitalisation for withdrawal.\n* Proven cognitive problems compromising understanding of the implications of the study and the proposed follow-up. proposed follow-up.\n* Serious decompensated somatic pathology.\n* Non-membership or non-beneficiaries of a national health insurance scheme.\n* Person protected by law, under guardianship or curatorship.\n* Not having signed free and informed consent to participate in the research.\n* Simultaneous participation in another clinical trial.",{"count":383,"type":23},104,[26],"The aim of this clinical study is to evaluate the efficacy of reinforced inpatient aftercare versus usual care on the percentage of days of abstinence during the first year following withdrawal in adults with alcohol use disorders undergoing inpatient withdrawal. The hypothesis is that reinforced post-withdrawal follow-up, of the motivational interview type, during the first 4 months following hospitalisation, in addition to the usual care, would allow :\n\n* Increase the percentage of days of abstinence in the year following withdrawal.\n* Reduce the rate of relapse in the year following withdrawal.\n* An increase in the cumulative and maximum duration of abstinence, an increase in motivation to maintain the change initiated and a reduction in the use of other substances in the year following withdrawal.\n* A reduction in the impact of risk factors involved in the relapse process in the year following withdrawal.\n\nAll participants will have assessments to monitor their abstinence and consumption. In addition to their assessments, the experimental group will have motivational talks once every 15 days.",[387,388,389,390,391],"Alcohol Use Disorder","Addiction","Alcohol Withdrawal","Motivational Interviews","Relapse",{"date":184,"type":36},{"date":394,"type":36},"2024-12-18",{"date":396,"type":23},"2028-01-13",{"name":42,"class":43},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":24,"phases":407,"briefSummary":408,"conditions":409,"keywords":412,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":423},"100552429","addictological-intervention-in-liver-transplantation-recipients-100552429","NCT06472973","ADDICTOlogical Intervention in LIVEr Transplantation Recipients","AddictoLIVE","Inclusion Criteria:\n\n* Aged 18 years or above\n* Hospitalized for LT for AALD as primary, secondary or tertiary indication\n* Discharged from intensive care unit to hepatology or surgery wards\n\nExclusion Criteria:\n\n* Severe alcohol-associated hepatitis as primary indication for liver transplantation\n* Impossibility of patient follow up over the next 2 years\n* General criteria:\n\n  * Refusal or absence of informed consent,\n  * Non-affiliation to the French national health insurance,\n  * Persons placed under legal protection, guardianship or curatorship",{"count":406,"type":23},720,[26],"Transplantation for end-stage-liver disease (ESLD) in the context of Alcohol-Associated Liver Disease (AALD) has been increasing and represents the main indication for Liver Transplantation (LT) in the world. Alcohol Use Disorder (AUD) is considered a brain chronic disease and requires a transdisciplinary approach that includes medical treatment and behavioral interventions.\n\nIn the context of LT, alcohol relapse occurs in 26 % up to 50% of LT recipients. Among Liver transplant recipients for AALD, severe alcoholic relapse (defined as more than 3 alcoholic drinks per day for women and 4\u002Fday for men) after LT leads to impaired longterm survival due to recurrent alcoholic cirrhosis (RAC), cardiovascular events and de novo cancer.\n\nSeveral strategies have been developed to prevent alcohol relapse. After LT, integrating an addiction team into the LT program has been advocated by the latest guidelines in Europe and the United States, in order to bring the management of alcohol-use disorder (AUD) in transplantation units, through the association of psychosocial and pharmacological interventions previously reported in AALD. However, those guidelines were based on descriptive studies, and the effect of this management needs to be confirmed through a randomized, controlled, multicenter study, involving centers that still do not include an addiction team in their LT programs.\n\nThis study will therefore assess prospectively and comparatively the impact of an addiction intervention after LT on return to alcohol use rates. We hypothesize that standardized targeted addiction monitoring of Liver Transplant recipients decreases the rates of alcohol relapse two years post-liver transplantation.",[410,411],"Alcohol Associated Liver Disease","Liver Transplantation",[413,414,415,416],"Liver transplantation","Addiction follow-up","Alcohol relapse","Survival",{"date":130,"type":36},{"date":419,"type":36},"2024-11-21",{"date":421,"type":23},"2030-11-21",{"name":42,"class":43},16,{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":53,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":24,"phases":434,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":443,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":44},"100543159","is-trogocytosis-a-predictive-marker-of-car-t-cell-response-in-diffuse-large-b-cell-lymphoma-100543159","NCT06352242","Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?","La Trogocytose Est-elle un Marqueur prédictif de la réponse Aux Cellules CAR-T Dans Les Lymphomes Diffus à Grandes Cellules B ?","CARTROG","Inclusion Criteria:\n\n* For patients\n\n  * Patient who has given free and informed consent in writing for inclusion in the non-interventional CART-BANK protocol, and orally for the CARTROG protocol,\n  * Patients over 18 years of age at the time of inclusion,\n  * Diagnosis of LDGCB,\n  * Decision to treat with anti-CD19 CAR-T cells,\n  * Patient affiliated to or benefiting from a social security scheme.\n* For healthy volunteers:\n\n  * Given free and informed oral consent for inclusion in the CARTROG protocol,\n  * Donor between 18 and 70 years of age at the time of inclusion,\n  * No history of solid cancer or hematological malignancy,\n  * No known chronic pathology (e.g. hypertension, diabetes, etc.) and no daily treatment,\n  * No surgical treatment within the last 6 months.\n\nExclusion Criteria:\n\n* Patients who do not meet all the inclusion criteria,\n* Pregnant or breast-feeding patient,\n* Patient unable to follow the procedures and\u002For frequency of visits planned in the trial, for psychological, family, social or geographical reasons,\n* Patient unable to consent freely to inclusion, under guardianship, curatorship or safeguard of justice.",{"count":433,"type":23},85,[26],"CAR-T cell therapy has improved survival in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL R\u002FR). However, only 65% of patients achieve a complete metabolic response after this treatment. To date, there is no predictive test for therapeutic response after injection of CAR-T cells. Recent studies have shown that the level of trogocytosis by immune cells correlates with the persistence of tumor cells in patients with hematological malignancies. Our main objective is to identify a phenotypic \"signature\" of trogocytosis predictive of therapeutic response 6 months after injection of CAR-T cells for DLBCL.",[437],"Diffuse Large B Cell Lymphoma",[439,440,441,442],"lymphoma","chimeric antigen receptor T-cell","trogocytosis","prognosis",{"date":130,"type":36},{"date":445,"type":36},"2024-05-22",{"date":447,"type":23},"2027-02-22",{"name":42,"class":43},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":458,"conditions":459,"keywords":464,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":75},"100538206","french-assessment-of-mrd-by-liquid-biopsies-in-stage-iii-crc-patients-frenchmrdcrc-100538206","NCT06287814","French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Stage III Colorectal Patients","FRENCH.MRD.CRC PART I Inclusion criteria\n\n* Colon or rectal cancer, clinical tumor stage I-III.\n* Patient 18 years or older.\n* Scheduled for curative intent resection surgery (including \"compromised\" curative resections).\n\nExclusion criteria\n\n* Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome.\n* Verified distant metastases.\n* Malignant colorectal polyps diagnosed after polypectomy.\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Protected and vulnerable adult\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.\n\nFRENCH.MRD.CRC PART II Inclusion criteria\n\n* Participation in FRENCH.MRD.CRC part 1 - SURGERY\n* Colorectal cancer, UICC stage III\n* Has received curative-intent resection and is a candidate for adjuvant chemotherapy (3- or 6-months regime) Exclusion criteria\n* Inflammatory bowel disease (Crohn's disease or ulcerative colitis) related colon cancer\n* Not treated with adjuvant chemotherapy despite indication (incomplete treatment not included)\n* Treated with neoadjuvant chemo-radiation therapy\n* Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)\n* Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study",{"count":457,"type":23},70,"Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.\n\nThere is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.\n\nThe GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.\n\nFRENCH-MRD-CRC is the French study of the european GUIDE.MRD project.",[460,461,462,463],"Colorectal Cancer","Stage III Colon Cancer","Minimal Residual Disease","Liquid Biopsy",[465,462,463],"Stage III colorectal cancer",{"date":130,"type":36},{"date":468,"type":36},"2024-04-11",{"date":470,"type":23},"2033-10-31",{"name":42,"class":43},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":481,"conditions":482,"keywords":486,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":44},"100538199","french-assessment-of-mrd-by-liquid-biopsies-in-colorectal-with-liver-metastasis-patients-frenchmrdcrlm-100538199","NCT06287723","French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)","French Assessment of Minimal Residual Disease by Liquid Biopsies in Colorectal With Liver Metastasis Patients","Inclusion Criteria:\n\n* Patient 18 years or older.\n* Colorectal cancer liver metastasis or metastases, according to the assessment of the MDT.\n* Metachronous and synchronous metastases will be included, as long as treatment intention of metastases resection is curative. In case of rare instances, where the liver metastases is removed before surgery of the primary tumor, postOP ctDNA is collected when the patient is considered completely tumor-free, i.e. after complete surgery of both the liver metastases and the primary tumor.\n* Treatment is planned with curative intent (patients treated with RFA can be included, BUT in these cases a tissue sample from the primary CRC tumor is a requisite)\n\nExclusion Criteria:\n\n* Hereditary colorectal cancer linked to familial colonic polyposis or Lynch syndrome.\n* Extrahepatic metastases\n* Malignant colorectal polyps diagnosed after polypectomy.\n* Synchronous colorectal and non-colorectal cancer diagnosed per operative (except skin cancer other than melanoma)\n* Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from eligibility screening\n* Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits) and\u002For otherwise considered by the Investigator to be unlikely to complete the study.\n* Liver cirrhosis\n* CRLM intervention\u002Fsurgery cannot be\u002Fwas not performed with curative intent\n* No tumor tissue available (preferably CRLM lesion, or alternatively primary tumor)\n* Pregnant or nursing woman, or in childbearing age and not willing to use contraception\n* Protected and vulnerable adult\n* Not covered by Health insurance\n* Patient unable to understand and sign written informed consent.",{"count":480,"type":23},30,"Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies. Currently, for colorectal cancer, the methods used to decide who gets additional post-surgery treatment are suboptimal. Some patients get too much treatment, while others do not get enough.\n\nThere is a new way to explore if there is any cancer left in a patient's body using circulating tumor DNA (ctDNA) detected in blood samples. This can help decide who needs more treatment after surgery. Even though many tests have been developed, it has yet to be determined which test performs best at relevant time points.\n\nThe GUIDE.MRD consortium is a group of experts, including scientists, technology, and pharmaceutical companies. The consortium is working on creating a reliable standard for the ctDNA tests, validating their clinical utility, and collecting data to help decide on the best treatment for each patient.\n\nFRENCH.MRD.CRLM is the French study and part of the european GUIDE.MRD project.",[460,483,484,462,463,485],"Liver Metastases","Stage IV Colorectal Cancer","ctDNA",[487,462,488],"Stage IV colorectal cancer","Liquid biopsy",{"date":130,"type":36},{"date":491,"type":36},"2024-04-15",{"date":493,"type":23},"2029-04-15",{"name":42,"class":43},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":503,"targetDuration":4,"studyType":24,"phases":505,"briefSummary":506,"conditions":507,"keywords":511,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":525},"100524894","nasal-high-flow-versus-non-invasive-ventilation-for-early-treatment-of-acute-exacerbation-of-chronic-obstructive-pulmonary-disease-with-hypercapnic-acidosis-100524894","NCT06114667","Nasal High Flow Versus Non-invasive Ventilation for Early Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Hypercapnic Acidosis","Nasal High Flow in Early Management of Patients Admitted to the Emergency Department for Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Hypercapnic Acidosis : a Randomized Controlled Non Inferiority Study","HiCOPD","Adult Patient admitted to the ED for acute exacerbation of COPD (AE-COPD)and respiratory acidosis (PaCO2 \\> 45 mmHg and pH \\\u003C7.35), for whom ventilatory assistance by NIV is indicated (SPLF 2017, GOLD2023 recommendations)\n\nInclusion Criteria:\n\n* Patients with ability to understand and give an informed consent\n* Patients affiliated with or who benefit from a social security\n* Patients admitted to the emergency department for a clinical suspicion of AE-COPD based on clinical history, physical examination and chest X-ray (SPLF 2017)\n* Patients with acute respiratory failure defined by: Respiratory rate ≥ 25 bpm AND\u002FOR Signs of respiratory failure (use of accessory respiratory muscles, paradoxical abdominal movement)\n* Patients with respiratory acidosis defined by PaCO2 \\> 45 mmHg AND pH \\\u003C 7.35 (measured on arterial blood gas)\n\nExclusion Criteria:\n\n* Patients who have already received NIV treatment before inclusion (including in-hospital or prehospital, with the exception of NIV at home)\n* Contraindication to non-invasive ventilation (SPLF 2017 and GOLD 2023 recommendations)\n* Patient uncooperative, agitated, opponent of the technique",{"count":504,"type":23},174,[26],"The purpose of this study is to determine whether nasal high flow is non inferior to non invasive ventilation (NIV) in the early treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and hypercapnic acidosis in the emergency department (ED). After obtaining informed consent, participants will be randomly assigned to receive either nasal high flow or non invasive ventilation (NIV, reference treatment) as respiratory support. Researchers will compare both respiratory support groups to see if their blood gas analysis and respiration return to normal ranges.",[508,509,510],"Acute Exacerbation of Chronic Obstructive Pulmonary Disease","Hypercapnic Acidosis","Respiratory Failure With Hypercapnia",[512,513,514,515,516,517,518],"respiratory insufficiency","Hypercapnic Acute Respiratory Failure","chronic obstructive pulmonary disease exacerbation","nasal high flow","non invasive ventilation","emergency department","critical are",{"date":130,"type":36},{"date":521,"type":36},"2026-06-16",{"date":523,"type":23},"2028-11-01",{"name":42,"class":43},3,{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":305,"minAge":19,"maxAge":534,"enrollmentInfo":535,"targetDuration":4,"studyType":24,"phases":537,"briefSummary":538,"conditions":539,"keywords":541,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":546,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":243},"100499952","hysteroscopy-vs-endouterine-aspiration-in-the-management-of-trophoblastic-retention-100499952","NCT05789940","Hysteroscopy vs. Endouterine Aspiration in the Management of Trophoblastic Retention","Hysteroscopy Versus Endouterine Aspiration in the Management of Trophoblastic Retention: A Prospective Randomized Multicenter Study","HARET","Inclusion Criteria:\n\n* Management for trophoblastic retention after early spontaneous miscarriage (\\\u003C14 weeks of amenorrhea)\n* Diagnosis of intrauterine trophoblastic retention by endovaginal pelvic ultrasound\n* Shared decision for surgical management\n\nExclusion Criteria:\n\n* Known uterine malformation\n* Patient who has received surgical treatment for current intrauterine retention\n* Patient with an intrauterine device (IUD)\n* Pregnancy obtained by medically assisted procreation\n* Indication for emergency surgical management for haemostatic purposes\n* Failure to obtain free, informed and written consent after a period of reflection\n* Person not affiliated or beneficiary of a national health insurance system\n* Person protected by law, under guardianship or curatorship\n* Person participating in other interventional research involving the human person","42 Years",{"count":536,"type":23},220,[26],"Introduction: Incomplete early miscarriage is defined as early miscarriage with persistent intrauterine material on ultrasound. Intrauterine retention of trophoblastic debris is not an uncommon phenomenon. These retentions may initially be asymptomatic but are often responsible for persistent metrorrhagia and endometritis. This symptomatology often accentuates the psychological distress of patients mourning the pregnancy. Incomplete miscarriages are mainly managed by the gynecological emergency department. The recommendations of the Collège National des Gynécologues et Obstétriciens Français (CNGOF) suggest as a first line of treatment: either surgical management or expectant care. The choice between the two is left to the discretion of the doctor and the patient. there are no clear recommendations as to the choice between hysteroscopy and aspiration. Within the teams, the choice is often made according to the habits and protocols of the service, according to the equipment available and the skills of the gynaecologists.\n\nAim: The main objective is to compare the efficacy of management by endo-uterine aspiration vs. management by hysteroscopy of trophoblastic retention after early miscarriage, at 6 weeks after surgery, by endovaginal ultrasound.\n\nMethods: This is a prospective, multicenter, randomized, open-label, two-arms, parallel therapeutic clinical trial comparing hysteroscopy versus endouterine aspiration for the management of trophoblastic retention after spontaneous miscarriage.\n\nPatients will be randomized (110 per arm) after verification of eligibility criteria and signature of consent, on the day of the operation:\n\n* Arm A: 110 patients treated by operative hysteroscopy\n* Arm B: 110 patients treated by endo-uterine aspiration",[540],"Miscarriage",[540,542,543,544,545],"Hysteroscopy","Aspiration","Fertility","Synechiae",{"date":130,"type":36},{"date":548,"type":36},"2023-09-18",{"date":550,"type":23},"2029-09-18",{"name":42,"class":43},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":24,"phases":562,"briefSummary":563,"conditions":564,"keywords":568,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":574,"leadSponsor":576,"locationsCount":75},"100465885","liquid-biopsy-and-pancreas-cancer-detection-of-axl-ctcs-ctc-axl-panc-100465885","NCT05346536","Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)","Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) Functional CTCs Using EPIDROP","CTC-AXL-PANC","Inclusion Criteria:\n\n* The patient is at least 18 years old;\n* Patients with pancreatic cancer with remote metastases, naïve of any treatment, that is, eligible for a first line of treatment;\n* Patients with oral consent\n\nExclusion Criteria:\n\n* Non-affiliation or non-beneficiary of a Social Security regimen;\n* Frailty persons according to Article L1121-6 of the CSP;\n* Adult protected or unable to give consent as per Article L1121-8 of the CPMP;\n* Pregnant or lactating women as per MSC L1121-5.\n* Not included for monitoring difficulties (mutation, insufficient motivation, predictable poor compliance, priority associated pathology in care, etc.)",{"count":561,"type":23},63,[26],"In solid cancers, some more aggressive tumor cells actively detach from the primary lesion and then travel through the circulating compartment to reach distant organs and form micro-metastases. These circulating tumor cells (CTCs) that have become disseminated tumor cells (DTCs) flourish in their new environments and may remain dormant for many years after the complete resection of the primary tumor. Detecting CTCs in the blood is also relevant for assessing tumor progression, prognosis and therapeutic follow-up. The non-invasive, highly sensitive for CTCs analysis is called \"liquid biopsy\". Pancreatic adenocarcinoma and breast cancer remain among cancers of very poor prognosis and thus represent a major therapeutic challenge. In recent years, the Axl membrane tyrosine kinase receptor has been the target of growing interest. Activation of the Gas6\u002FAxl signaling pathway is associated with, among other things, tumor cell growth and survival, epithelial to mesenchymal transition (EMT) or drug resistances. In addition, Axl overexpression is frequently identified in patients with pancreatic adenocarcinoma and is associated with a poor prognosis. For example, the Laboratoire des Cellules Circulantes Rares Humaines (LCCRH) at the CHU and the University of Montpellier has developed two new \"CTC-AXL\" tests to detect CTCs expressing Axl: one using the CellSearch® (gold standard and FDA-approved) system and the other using the EPIDROP technique. The purpose of this research project is to assess the concordance of the \"CTC-AXL\" measurement by the innovative EPIDROP technique and the CellSearch® technique in patients with metastatic pancreatic or breast cancer.",[565,566,567],"Pancreatic Ductal Adenocarcinoma","Metastatic Pancreatic Cancer","Circulating Tumor Cell",[566,567,569,570],"AXL","CellSearch",{"date":130,"type":36},{"date":573,"type":36},"2022-06-16",{"date":575,"type":23},"2027-12-31",{"name":42,"class":43},{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":585,"minAge":114,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":24,"phases":587,"briefSummary":588,"conditions":589,"keywords":591,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":598,"leadSponsor":600,"locationsCount":243},"100405249","early-detection-of-prostate-cancer-100405249","NCT04556916","Early Detection of Prostate Cancer","Early Detection of Prostate Cancer by Liquid Biopsy","PROLIPSY","Inclusion Criteria Patient :\n\n* Men over 40 being suspicious of prostate cancer\n* Subject with PSA ≥ 4 and designated for biopsy\n* Subjects must be able to attend all scheduled visits and to comply with all trial procedures\n* mpMRI done before prostate biopsy\n* Subject must be covered by public health insurance\n* Signed informed consent form\n\nInclusion Criteria Subject Control Patient patient free from prostatic disease :\n\n* Men over 40 with no suspicion of prostate cancer\n* Subject with PSA \\\u003C 2.5 and normal digital rectal examination\n* Subject must be covered by public health insurance\n* Signed informed consent form\n\nExclusion Criteria Patient :\n\n* Subject with histologically confirmed prostate cancer\n* Subject with a verified viral infection (HIV or Hepatitis)\n* Subject under Finasteride treatment\n* Subject under hormonal treatment (analogs, antagonists, androgenics)\n* Subject with other cancer diagnosed\n* Subject unable to sign consent\n* Planned longer stay outside the region that prevents compliance with the visit plan\n* Subject deprived of liberty, protected adults or vulnerable persons\n* Urinary infection ≤ 2 months\n* Subject excluding health insurance registration\n* Subject refusing to perform prostate biopsy\n* Subject who are in a dependency or employment with the sponsor or the investigator\n\nExclusion Criteria Subject Control :\n\n* Subject with histologically confirmed prostate cancer\n* Subject with a verified viral infection (HIV or Hepatitis)\n* Subject under Finasteride treatment\n* Subject with other cancer diagnosed\n* Subject unable to sign consent\n* Planned longer stay outside the region that prevents compliance with the visit plan\n* Subject deprived of liberty, protected adults or vulnerable persons\n* Urinary infection ≤ 2 months\n* Subject excluding health insurance registration","MALE",{"count":328,"type":23},[26],"This study is the early detection of prostate cancer by analysing circulating bloodbased biomarkers. Based on our latest developments, we primarily aim to assess the validity of CTCs (circulating tumour cells) and tumour cell products circulating in blood (DNA, exosomes) for early PCa (Prostate cancer) detection.\n\nIn the first discovery period, the investigators will assess which Liquid biopsy marker will provide the best discrimination between the patients with histologically proven PCa and age-matched noncancer controls. Further subset analysis with special emphasis on the identification of high risk PCa patients with aggressive tumours as defined by a Gleason score (\"gold standard\") of 8 or higher (ISUP 4 and higher), will be performed. The resulting biomarker candidates will then be further explored in the subsequent training and validation study (years 2 and 3) in order to obtain the single blood test or combination of tests with the highest sensitivity and specificity for detection of early PCa and\u002For high-risk PCa. The investigators will also compare these new biomarkers with recently FDA cleared CE-IVD assays for early detection of prostate cancer, based on classic peripheral tumour markers, such as Prostate Health Index (PHI) and PCA3. Follow up evaluations will be initiated to assess the prognostic relevance of the candidate biomarkers determined in this project. Here, the investigators will set up the data management system including all relevant information on the tissues collected and the results of the analyses as well as the clinical data of the patients investigated in this study.",[590],"Prostate Cancer",[592,593,594],"prostate cancer","liquid biopsy","circulating tumour cells",{"date":130,"type":36},{"date":597,"type":36},"2021-02-19",{"date":599,"type":23},"2033-09-15",{"name":42,"class":43},{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":609,"enrollmentInfo":610,"targetDuration":4,"studyType":24,"phases":611,"briefSummary":612,"conditions":613,"keywords":615,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":618,"startDateStruct":619,"completionDateStruct":621,"leadSponsor":623,"locationsCount":75},"100406386","pilot-study-for-thyroid-surgery-by-preoperative-video-support-and-personalized-and-secure-web-platform-100406386","NCT04571736","Pilot Study for Thyroid Surgery by Preoperative Video Support and Personalized and Secure Web Platform","Interest of Improving Preoperative Medical Information by Video Support and Personalized and Secure Web Platform: Pilot Study in Thyroid Surgery (AMEDOP)","AMEDOP","Inclusion Criteria:\n\n* Age between 18 and 75,\n* Indication of lobo-isthmectomy or total thyroidectomy\n* Compliance for the completion of self-questionnaires\n* Person affiliated or beneficiary of a social security scheme.\n* Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Difficulty understanding the French language\n* Lack of internet access\n* Persons placed under the protection of justice,\n* Person under guardianship or curatorship\n* Person participating in another research including an exclusion period still in progress,\n* Subject with severely impaired physical and \u002F or psychological health, which, according to the investigator, may affect the compliance of the study participant\n* Pregnant \u002F lactating woman","75 Years",{"count":536,"type":23},[26],"The medical information delivered to the patient before any surgery constitutes an essential and compulsory step during the initial management of the operated patient.\n\nThere are different reasons for the quantity and quality of medical information retained by the patient. An internet platform with personalized and secure access has been developed. This platform contains, among other things, an explanatory video of thyroid surgery and allows the patient to have access to information on surgical management at any time.\n\nThe investigators believe that unlimited access for the duration of the study to this platform could reduce the preoperative anxiety level of patients.",[614],"Thyroid",[616,617],"Preoperative Procedure","Instructional Films and Video",{"date":130,"type":36},{"date":620,"type":36},"2020-11-18",{"date":622,"type":23},"2027-03-18",{"name":42,"class":43},{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":630,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":634,"conditions":635,"keywords":637,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":642,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":75},"100390947","discovery-of-soluble-biomarkers-for-pancreatic-cancer-using-innovative-all-patient-inclusive-methodology-100390947","NCT04370574","Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology","Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology (PanEXPEL2)","PanEXPEL2","Inclusion Criteria:\n\n* Patient with pancreatic mass and suspicion of pancreatic ductal adenocarcinoma requiring endoscopic ultrasound with fine needle biopsy\n\nExclusion Criteria:\n\n* Vulberable person according to L1121-6 of Public health reglementation in France\n* Pregnant women",{"count":633,"type":23},200,"Pancreatic ductal adenocarcinoma (PDAC) remains among cancers with a very poor prognosis (1-year survival \\\u003C20%). Endoscopic ultrasound with fine needle aspiration (EUS\u002FFNA) is the common examination for all patients with suspicious pancreatic mass. A method was recently developed : it preserves the sanitary sample, named EXPEL, which allows standard pathology examination and OMICS analyzes from the \"rinse\" liquid. After EUS\u002FFNA in clinical practice, the content of the needle is rinsed in CytoLyt® preservative solution. After cytofiltration, this liquid is systematically discarded.\n\nBased on the EXPEL concept, we hypothesise that this all-patients inclusive approach (\"Modified EXPEL\" procedure) combined with the methodology to access proteomic and metabolomics information in these original samples will allow us to identify a series of clinically useful marker signatures that will ultimately be measurable, non-invasively, in the patient blood.",[636],"Pancreatic Neoplasms",[638,639,640,641],"Biopsy","Fine-Needle","diagnostic imaging","Endosonography",{"date":130,"type":36},{"date":644,"type":36},"2021-01-14",{"date":646,"type":23},"2027-07",{"name":42,"class":43},{"id":649,"slug":650,"hasResults":12,"nctId":651,"briefTitle":652,"officialTitle":653,"acronym":654,"eligibilityCriteria":655,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":656,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":658,"conditions":659,"keywords":661,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":664,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":75},"100384768","collection-of-biological-samples-from-patients-treated-with-car-t-cells-for-hematological-malignancies-100384768","NCT04290000","Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies","Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies in Montpellier University Hospital","CAR-T BANK","Inclusion Criteria:\n\n* patient treated by CAR-T cell at the University Hospital of Montpellier\n\nExclusion Criteria:\n\n* refusal to sign consent form\n* pregnant woman\n* major protected",{"count":657,"type":23},300,"Development of CAR-T cell against CD19 B lymphoma and Acute Lymphoblastic Leukemia leaded to 2 authorized medication: Yescarta and Kymriah. Despite impressive outcomes in 3 phase II studies, never met in relapsed or refractory diseases, half of the patients don't respond to this treatment.This can be explained by a low expansion, functional alteration or short persistence of infused cells. Determination of reasons for treatment failure is the first step for optimization of this therapeutics. This project aims to bank blood samples from a cohort of patients treated with CAR-T cell for hematological malignancies in Montpellier University Hospital. Clinical data related to samples will be collected. This samples will be used to determine factors influencing efficacy of CAR-T cells treatments.",[660],"Lymphoma and Acute Lymphoblastic Leukemia",[662,439,663],"CAR T-Cell","Acute Lymphoblastic Leukemia",{"date":130,"type":36},{"date":666,"type":36},"2020-03-27",{"date":668,"type":23},"2040-03-27",{"name":42,"class":43},""]